# What to watch when a joint treatment begins *Joint Regeneration Glendale | What Results Can Tell You* > Joint regeneration Glendale facts on soreness, movement and what to track before and after a non-surgical joint treatment. A deep ache may arrive before the first errand on some mornings. During a quiet week, soreness may ease even when the worn joint hasn't changed. Daily tasks give a fairer account of how the joint is doing over time. Your walking, sleep and reach toward a shelf can show whether life is getting easier week by week at home. Use the same chore when you compare one week with the next. Changing the task each time can make a small gain or setback look larger than it is. ## What to measure before care starts Choose a few tasks that matter and record them before the first clinic visit. Note how far you walk, how often soreness wakes you and whether standing from a chair is hard. That short record tells the clinic what the joint allowed before care. It also keeps one unusually good or bad day from shaping the whole account. ## What to notice after a procedure Early soreness after a shot may feel different from the older joint ache. Ask how long that new soreness may last and which symptoms mean you need to call. Later, compare the same chores with notes made before care began. Real relief means easier movement, sleep or work, not merely a lower score. ## What to ask when a promise sounds too large Platelet-rich plasma, or PRP, begins with a draw of the person's own blood. The blood is spun to gather platelets, small parts that stop bleeding, for a joint-area shot. Keep doing the home exercises agreed on with your doctor, and track the same chores. QC Kinetix offers PRP as one non-surgical choice after its medical team reviews your needs. ## Sources 1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 4. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 5. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations. Zhang EJX, et al. — [Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.](https://pubmed.ncbi.nlm.nih.gov/42221207/). *Orthopaedic journal of sports medicine*, 2026. DOI: 10.1177/23259671261443876. ## What to bring to the clinic Bring notes on the soreness, a medicine list and records from earlier care. QC Kinetix can review those details and discuss a non-surgical shot prepared from a person's own blood. The Peoria office may suit north Glendale, while Banner Estrella may be simpler from the south side. Call (602) 837-PAIN to ask about scheduling. Talk to the clinic team: --- Clear answers for a sore joint. Joint regeneration Glendale information on common soreness, home care, warning signs, visits and non-surgical choices near home. Plain information about aching joints, useful home steps, clinic exams and non-surgical choices near Glendale. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Peoria and Banner Estrella locations referenced here, and the business benefits when readers book a consultation. Copyright 2026 Glendale Joint Field Guide. General education only; it does not replace an examination or individualized medical advice.